Full-Time

Manager 1

Program Manufacturing & Supply Chain

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$109.5k - $153.3k/yr

+ Bonus + Equity

Irvine, CA, USA

Hybrid

Hybrid work environment; remote work is an option.

Category
Operations & Logistics (2)
,
Required Skills
Financial analysis
Risk Management
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor of Science in one of the relevant Engineering or Science fields
  • Minimum of 5 years working in Manufacturing, Supply Chain, and/or CMC in biotech or pharmaceutical industry, with at least 2 years of success in a project management role
  • Good understanding and experience of pharmaceutical manufacturing and CMC with respect to GMP, quality systems, ICH guidelines, FDA and associated regulatory requirements
  • Proficient use of IT / project management tools (Outlook, Excel, MS Project)
  • Ability to negotiate and sustain networking relationships in a matrix environment
  • Some travel may be required – up to 10%
  • Excellent communication, influencing, stakeholder management and decision-making skills
Responsibilities
  • Work closely with cross functional teams including Manufacturing Operations, Supply Chain, Quality, CMC, and Program Management to ensure alignment and integration of timelines, requirements, and priorities
  • Collaborates with and helps to manage external resources including contract manufacturing partners (e.g., CMO, CDMO) and consultants to ensure achievement of specified timelines, scope and deliverables
  • Facilitates and organizes effective and efficient team meetings including scheduling, agenda setting, material preparation, key decisions, action items and minutes
  • Create and maintain manufacturing batch timelines to ensure on-time delivery
  • In concert with a cross-functional team, identifies and manages technical, operational, and quality risks as well as helps to develop mitigation measures and contingency plans
  • Communicates decisions, status, risks, and issues within the technical teams and management, including appropriate escalation
  • Accountable for tracking program budget versus actuals, including data collection, analysis, and ongoing assessment of financial performance
  • Maintain and update program dashboards to reflect changes in timelines, scope, and budget, and proactively escalate variances or risks as appropriate
  • Collaborate within integrated leadership operating models to support cross-functional decision-making, prioritization, and execution
  • Contributes to the standardization of PM best practices at Tarsus
Desired Qualifications
  • PMP is preferred as a strong project or program management foundation
  • Experience in aseptic manufacturing is preferred
  • Experience successfully managing third party contractors in contract manufacturing organizations is highly preferred
  • Decision Making competency demonstrated through applying structured analysis to complex challenges, balancing competing priorities and long-term impacts while engaging stakeholders and driving solutions aligned with organizational goals
  • Collaboration and Team Building competency demonstrated by promoting cross-functional collaboration, aligning diverse teams around shared goals, fostering healthy debate and building networks
  • Outcome Driven competency demonstrated by aligning teams around shared priorities, proactively addressing risks and dependencies, and driving cross-functional accountability to deliver results
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tarsus Pharamceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).